Search
Research
Bile signalling promotes chronic respiratory infections and antibiotic toleranceBile acid signalling is a leading trigger for the development of chronic phenotypes underlying the pathophysiology of chronic respiratory disease
Research
Productive infection of human embryonic stem cell-derived nkx2.1+ respiratory progenitors with human rhinovirus.Our experiments provide proof of principle for the use of PSC-derived respiratory epithelial cells in the study of cell-virus interactions.
Research
Early pulmonary inflammation and lung damage in children with cystic fibrosisAirway inflammation and infection are present from early in life, often before children are symptomatic.
Research
Multi-modality monitoring of cystic fibrosis lung disease: the role of chest computed tomographyStratification of monitoring protocols based on the risk profile of the patient can help us in the future to better care for people with Cystic Fibrosis.
Research
Transcription factor p63 regulates key genes and wound repair in human airway epithelial Basal cellsThe airway epithelium in asthma displays altered repair and incomplete barrier formation.
Research
BANK CF: The Respiratory Centre BIOBANKThe Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) program has grown from an early surveillance program initiated in Perth in 1999, which performed bronchoalveolar lavage (BAL) to evaluate pulmonary infection and inflammation, as well as infant lung function testing.
Research
SHIP CT: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial.SHIP-CT, led by Professor Stephen Stick, Director of the Wal-yan Respiratory Research Centre at The Kids, is a unique study in preschool-aged children (from 3-6 years of age) with CF using images of the lung from chest CT scans as the main outcome measure.
Research
tesG expression as a potential clinical biomarker for chronic Pseudomonas aeruginosa pulmonary biofilm infectionsPseudomonas aeruginosa infections in the lungs affect millions of children and adults worldwide. To our knowledge, no clinically validated prognostic biomarkers for chronic pulmonary P. aeruginosa infections exist. Therefore, this study aims to identify potential prognostic markers for chronic P. aeruginosa biofilm lung infections.
Research
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case seriesEnsitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.